Last 12 months
Inside the activity.
1 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 13 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2019 Filed Jan 3, 2019 20:22 UTC |
MACARTNEY LAWSONDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001209191-19-001561 · doc4.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-01-02 Read SEC document |
| September 25, 2018 Filed Sep 28, 2018 01:25 UTC |
LIGAND PHARMACEUTICALS INC10% owner
|
SaleCommon Stock | 262,881 | $19.15 | $5,034,250.01 |
DisclosureSEC source: 0000899243-18-025453 · doc4.xml · nonDerivative · entry 1 LIGAND PHARMACEUTICALS INC · CIK 0000886163 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,038,083 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.74, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 882,474 shares of Common Stock held by Metabasis Therapeutics, Inc., a wholly owned subsidiary of the Reporting Person. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 17:25 UTC |
Masamune HirokoChief Development Officer
|
GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001209191-18-041236 · doc4.xml · derivative · entry 2 Masamune Hiroko · CIK 0001745341 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2028-07-01 F2 · derivative.exercise_date: One-third of the shares subject to the option will vest on each one year anniversary of the grant date. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 17:25 UTC |
Masamune HirokoChief Development Officer
|
GrantCommon Stock, par value $0.00001 per share | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-041236 · doc4.xml · nonDerivative · entry 1 Masamune Hiroko · CIK 0001745341 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,197 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| May 31, 2018 Filed May 31, 2018 19:04 UTC |
SINGLETON J MATTHEWDirector
|
PurchaseCommon Stock, par value $0.00001 per share | 9,500 | $9.82 | $93,260.55 |
DisclosureSEC source: 0001209191-18-034496 · doc4.xml · nonDerivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Read SEC document |
| May 31, 2018 Filed May 31, 2018 19:03 UTC |
MORNEAU MICHAELVP, Finance and Administration
|
SaleCommon Stock, par value $0.00001 per share | 21,551 | $9.25 | $199,346.75 |
DisclosureSEC source: 0001209191-18-034494 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,035 F1 · shares: All 21,551 of the shares were acquired on May 18, 2018 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| May 29, 2018 Filed May 31, 2018 22:59 UTC |
Webster Stephen WDirector
|
PurchaseCommon Stock, par value $0.00001 per share | 8,000 | $5.21 | $41,712.00 |
DisclosureSEC source: 0001209191-18-034485 · doc4.xml · nonDerivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.203 to $5.216, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 29, 2018 Filed May 31, 2018 19:02 UTC |
Rowland Charles A JrDirector
|
PurchaseCommon Stock, par value $0.00001 per share | 30,000 | $5.16 | $154,800.00 |
DisclosureSEC source: 0001209191-18-034490 · doc4.xml · nonDerivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.06 to $5.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 29, 2018 Filed May 31, 2018 18:57 UTC |
MACARTNEY LAWSONDirector
|
PurchaseCommon Stock, par value $0.00001 per share | 47,965 | $5.22 | $250,329.34 |
DisclosureSEC source: 0001209191-18-034482 · doc4.xml · nonDerivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,965 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.1417 to $5.2412, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 21, 2018 Filed Sep 28, 2018 01:25 UTC |
LIGAND PHARMACEUTICALS INC10% owner
|
OtherConvertible Note (convertible into Common Stock) · Derivative | 1,916,509 | $1,916,509.00 | $3,673,006,747,081.00 |
DisclosureSEC source: 0000899243-18-025453 · doc4.xml · derivative · entry 3 LIGAND PHARMACEUTICALS INC · CIK 0000886163 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed F3 · derivative.exercise_price: The Convertible Notes were repurchased in full by the Issuer on May 23, 2018. The Convertible Notes were convertible at a price per share equal to the lesser of (1) (x) if the conversion occurs within 180 days of April 13, 2016, $1.25, or (y) if the conversion occurs after October 10, 2016, the volume weighted average closing price of the Common Stock, as reported by The Nasdaq Stock Market LLC, for the thirty (30) consecutive trading days ending on the last trading date immediately preceding the date of conversion, and (2) $8.00 (as adjusted for any and all stock dividends, stock splits, stock combinations or other similar transactions). F6 · kind: Represents repayment in full by the Issuer of the Convertible Notes. F5 · derivative.exercise_date: The Convertible Note was convertible on or after May 21, 2018 (the "Maturity Date"). In addition, prior to the Maturity Date, the Issuer has the option to prepay part of all of the outstanding Convertible Notes in which case the Reporting Person has the option to receive the prepayment in cash or shares of Common Stock, subject to certain conditions. F5 · derivative.expiration_date: The Convertible Note was convertible on or after May 21, 2018 (the "Maturity Date"). In addition, prior to the Maturity Date, the Issuer has the option to prepay part of all of the outstanding Convertible Notes in which case the Reporting Person has the option to receive the prepayment in cash or shares of Common Stock, subject to certain conditions. F3 · derivative.underlying_shares: The Convertible Notes were repurchased in full by the Issuer on May 23, 2018. The Convertible Notes were convertible at a price per share equal to the lesser of (1) (x) if the conversion occurs within 180 days of April 13, 2016, $1.25, or (y) if the conversion occurs after October 10, 2016, the volume weighted average closing price of the Common Stock, as reported by The Nasdaq Stock Market LLC, for the thirty (30) consecutive trading days ending on the last trading date immediately preceding the date of conversion, and (2) $8.00 (as adjusted for any and all stock dividends, stock splits, stock combinations or other similar transactions). Read SEC document |
| May 04, 2018 Filed May 8, 2018 20:37 UTC |
MORNEAU MICHAELVP, Finance and Administration
|
Tax withholdingCommon Stock, par value $0.00001 per share | 7,616 | $4.22 | $32,139.52 |
DisclosureSEC source: 0001209191-18-028718 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,035 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock. Read SEC document |
| May 04, 2018 Filed May 9, 2018 00:37 UTC |
Lian BrianDirector · President & CEO
|
Tax withholdingCommon Stock, par value $0.00001 per share | 10,086 | $4.22 | $42,562.92 |
DisclosureSEC source: 0001209191-18-028717 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,483,012 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 17:42 UTC |
MORNEAU MICHAELChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001209191-18-004973 · doc4.xml · derivative · entry 2 MORNEAU MICHAEL · CIK 0001517780 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2028-01-19 F3 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 17:42 UTC |
MORNEAU MICHAELChief Financial Officer
|
GrantCommon Stock, par value $0.00001 per share | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-004973 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,651 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. F2 · balance_after: Includes 3,004 shares acquired on May 19, 2017 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 3,043 shares acquired on November 20, 2017 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 22:41 UTC |
Lian BrianDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001209191-18-004972 · doc4.xml · derivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2028-01-19 F2 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 22:41 UTC |
Lian BrianDirector · President & CEO
|
GrantCommon Stock, par value $0.00001 per share | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-004972 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,493,098 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:18 UTC |
Webster Stephen WDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-18-000858 · doc4.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-02 Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 16:17 UTC |
SINGLETON J MATTHEWDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-18-000853 · doc4.xml · derivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-02 Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:15 UTC |
FOEHR MATTHEW WDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-18-000834 · doc4.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-02 Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 16:17 UTC |
Rowland Charles A JrDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-18-000848 · doc4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-02 Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 16:16 UTC |
MACARTNEY LAWSONDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-18-000840 · doc4.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-02 Read SEC document |
| July 13, 2017 Filed Sep 28, 2018 01:25 UTC |
LIGAND PHARMACEUTICALS INC10% owner
|
OtherConvertible Note (convertible into Common Stock) · Derivative | 38,630 | $38,630.00 | $1,492,276,900.00 |
DisclosureSEC source: 0000899243-18-025453 · doc4.xml · derivative · entry 2 LIGAND PHARMACEUTICALS INC · CIK 0000886163 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,916,509 Underlying: Common Stock · Not disclosed shares Expires not disclosed F3 · derivative.exercise_price: The Convertible Notes were repurchased in full by the Issuer on May 23, 2018. The Convertible Notes were convertible at a price per share equal to the lesser of (1) (x) if the conversion occurs within 180 days of April 13, 2016, $1.25, or (y) if the conversion occurs after October 10, 2016, the volume weighted average closing price of the Common Stock, as reported by The Nasdaq Stock Market LLC, for the thirty (30) consecutive trading days ending on the last trading date immediately preceding the date of conversion, and (2) $8.00 (as adjusted for any and all stock dividends, stock splits, stock combinations or other similar transactions). F4 · kind: Represents repayment by the Issuer of the Convertible Notes. F5 · derivative.exercise_date: The Convertible Note was convertible on or after May 21, 2018 (the "Maturity Date"). In addition, prior to the Maturity Date, the Issuer has the option to prepay part of all of the outstanding Convertible Notes in which case the Reporting Person has the option to receive the prepayment in cash or shares of Common Stock, subject to certain conditions. F5 · derivative.expiration_date: The Convertible Note was convertible on or after May 21, 2018 (the "Maturity Date"). In addition, prior to the Maturity Date, the Issuer has the option to prepay part of all of the outstanding Convertible Notes in which case the Reporting Person has the option to receive the prepayment in cash or shares of Common Stock, subject to certain conditions. F3 · derivative.underlying_shares: The Convertible Notes were repurchased in full by the Issuer on May 23, 2018. The Convertible Notes were convertible at a price per share equal to the lesser of (1) (x) if the conversion occurs within 180 days of April 13, 2016, $1.25, or (y) if the conversion occurs after October 10, 2016, the volume weighted average closing price of the Common Stock, as reported by The Nasdaq Stock Market LLC, for the thirty (30) consecutive trading days ending on the last trading date immediately preceding the date of conversion, and (2) $8.00 (as adjusted for any and all stock dividends, stock splits, stock combinations or other similar transactions). Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 21:34 UTC |
Rowland Charles A JrDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-17-043855 · doc4.xml · derivative · entry 1 Rowland Charles A Jr · CIK 0001383292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-07-01 Read SEC document |
| May 04, 2017 Filed May 5, 2017 18:25 UTC |
MORNEAU MICHAELChief Financial Officer
|
Tax withholdingCommon Stock, par value $0.00001 per share | 8,192 | $1.34 | $10,977.28 |
DisclosureSEC source: 0001209191-17-030443 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,604 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock. F2 · balance_after: Includes 147 shares acquired on May 20, 2015 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, 2,643 shares acquired on November 20, 2015 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, 5,694 shares acquired on May 20, 2016 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, and 2,908 shares acquired on November 18, 2016 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 05, 2017 Filed Jan 5, 2017 19:20 UTC |
MORNEAU MICHAELChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 17,605 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-17-002391 · doc4.xml · derivative · entry 2 MORNEAU MICHAEL · CIK 0001517780 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,605 Underlying: Common Stock · 17,605 shares Expires 2027-01-05 F2 · shares: The Reporting Person's employment agreement with the Issuer entitles him to an annual cash bonus. The Reporting Person voluntarily elected to be paid 20% of his 2016 annual cash bonus in the form of an option to purchase shares of common stock of the Issuer. Read SEC document |
| January 05, 2017 Filed Jan 5, 2017 19:20 UTC |
MORNEAU MICHAELChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-17-002391 · doc4.xml · derivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2027-01-05 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 00:20 UTC |
Lian BrianDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 34,931 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-17-002389 · doc4.xml · derivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,931 Underlying: Common Stock · 34,931 shares Expires 2027-01-05 F2 · shares: The Reporting Person's employment agreement with the Issuer entitles him to an annual cash bonus. The Reporting Person voluntarily elected to be paid 25% of his 2016 annual cash bonus in the form of an option to purchase shares of common stock of the Issuer. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 00:20 UTC |
Lian BrianDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-17-002389 · doc4.xml · derivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-01-05 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 00:16 UTC |
Webster Stephen WDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-17-002382 · doc4.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-01-03 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:17 UTC |
SINGLETON J MATTHEWDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-17-002384 · doc4.xml · derivative · entry 1 SINGLETON J MATTHEW · CIK 0001243514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-01-03 Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 00:18 UTC |
FOEHR MATTHEW WDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-17-002387 · doc4.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-01-03 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:15 UTC |
MACARTNEY LAWSONDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-17-002379 · doc4.xml · derivative · entry 1 MACARTNEY LAWSON · CIK 0001606831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-01-03 Read SEC document |
| November 15, 2016 Filed Nov 15, 2016 21:34 UTC |
FOEHR MATTHEW WDirector
|
PurchaseCommon Stock, par value $0.00001 per share | 13,000 | $1.21 | $15,678.00 |
DisclosureSEC source: 0001209191-16-150191 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,250 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.1999 to $1.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.